Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer.

De Laere B, Oeyen S, Mayrhofer M, Whitington T, van Dam PJ, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert EG, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff IE, van Dam V, Brouwer A, Goossens D, Heyrman L, Van den Eynden GG, Rutten A, Del Favero J, Rantalainen M, Rajan P, Sleijfer S, Ullén A, Yachnin J, Grönberg H, Van Laere SJ, Lindberg J, Dirix LY.

Clin Cancer Res. 2018 Sep 12. pii: clincanres.1943.2018. doi: 10.1158/1078-0432.CCR-18-1943. [Epub ahead of print]

PMID:
30209161
2.

Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer.

Reddy JP, Atkinson RL, Larson R, Burks JK, Smith D, Debeb BG, Ruffell B, Creighton CJ, Bambhroliya A, Reuben JM, Van Laere SJ, Krishnamurthy S, Symmans WF, Brewster AM, Woodward WA.

Breast Cancer Res Treat. 2018 Sep;171(2):283-293. doi: 10.1007/s10549-018-4835-6. Epub 2018 Jun 1.

PMID:
29858753
3.

MicroRNA profiling in plasma samples using qPCR arrays: Recommendations for correct analysis and interpretation.

Gevaert AB, Witvrouwen I, Vrints CJ, Heidbuchel H, Van Craenenbroeck EM, Van Laere SJ, Van Craenenbroeck AH.

PLoS One. 2018 Feb 23;13(2):e0193173. doi: 10.1371/journal.pone.0193173. eCollection 2018.

4.

XIAP Regulation by MNK Links MAPK and NFκB Signaling to Determine an Aggressive Breast Cancer Phenotype.

Evans MK, Brown MC, Geradts J, Bao X, Robinson TJ, Jolly MK, Vermeulen PB, Palmer GM, Gromeier M, Levine H, Morse MA, Van Laere SJ, Devi GR.

Cancer Res. 2018 Apr 1;78(7):1726-1738. doi: 10.1158/0008-5472.CAN-17-1667. Epub 2018 Jan 19.

PMID:
29351901
5.

Increased Angiogenesis and Lymphangiogenesis in Metastatic Sentinel Lymph Nodes Is Associated With Nonsentinel Lymph Node Involvement and Distant Metastasis in Patients With Melanoma.

Pastushenko I, Van den Eynden GG, Vicente-Arregui S, Prieto-Torres L, Alvarez-Alegret R, Querol I, Dirix LY, Carapeto FJ, Vermeulen PB, Van Laere SJ.

Am J Dermatopathol. 2016 May;38(5):338-46. doi: 10.1097/DAD.0000000000000488.

PMID:
26909582
6.

Systems biology analysis reveals NFAT5 as a novel biomarker and master regulator of inflammatory breast cancer.

Remo A, Simeone I, Pancione M, Parcesepe P, Finetti P, Cerulo L, Bensmail H, Birnbaum D, Van Laere SJ, Colantuoni V, Bonetti F, Bertucci F, Manfrin E, Ceccarelli M.

J Transl Med. 2015 May 1;13:138. doi: 10.1186/s12967-015-0492-2.

7.

Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management.

van Schooneveld E, Wildiers H, Vergote I, Vermeulen PB, Dirix LY, Van Laere SJ.

Breast Cancer Res. 2015 Feb 18;17:21. doi: 10.1186/s13058-015-0526-y. Review.

8.

Circulating tumour cells and lung microvascular tumour cell retention in patients with metastatic breast and cervical cancer.

Peeters DJ, Brouwer A, Van den Eynden GG, Rutten A, Onstenk W, Sieuwerts AM, Van Laere SJ, Huget P, Pauwels P, Peeters M, Vermeulen PB, Dirix LY.

Cancer Lett. 2015 Jan 28;356(2 Pt B):872-9. doi: 10.1016/j.canlet.2014.10.039. Epub 2014 Nov 4.

PMID:
25449778
9.

Tumor stromal phenotypes define VEGF sensitivity--letter.

Van den Eynden GG, Bird NC, Dirix LY, Eefsen RL, Gao ZH, Høyer-Hansen G, Illemann M, Majeed AW, Metrakos P, Reynolds AR, Vainer B, van Dam PJ, Van Laere SJ, Vermeulen PB, Vidal-Vanaclocha F, Brodt P; Liver Metastasis Research Network.

Clin Cancer Res. 2014 Oct 1;20(19):5140. doi: 10.1158/1078-0432.CCR-14-0158. No abstract available.

10.

Squamous cell carcinomas of the skin explore angiogenesis-independent mechanisms of tumour vascularization.

Pastushenko I, Gracia-Cazaña T, Vicente-Arregui S, Van den Eynden GG, Ara M, Vermeulen PB, Carapeto FJ, Van Laere SJ.

J Skin Cancer. 2014;2014:651501. doi: 10.1155/2014/651501. Epub 2014 May 6.

11.

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.

Bidard FC, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Lebofsky R, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Bottini A, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Johannes H, Reis-Filho JS, Pantel K, Pierga JY, Michiels S.

Lancet Oncol. 2014 Apr;15(4):406-14. doi: 10.1016/S1470-2045(14)70069-5. Epub 2014 Mar 11.

PMID:
24636208
12.

A core invasiveness gene signature reflects epithelial-to-mesenchymal transition but not metastatic potential in breast cancer cell lines and tissue samples.

Marsan M, Van den Eynden G, Limame R, Neven P, Hauspy J, Van Dam PA, Vergote I, Dirix LY, Vermeulen PB, Van Laere SJ.

PLoS One. 2014 Feb 21;9(2):e89262. doi: 10.1371/journal.pone.0089262. eCollection 2014.

13.

Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer.

Liu NQ, Stingl C, Look MP, Smid M, Braakman RB, De Marchi T, Sieuwerts AM, Span PN, Sweep FC, Linderholm BK, Mangia A, Paradiso A, Dirix LY, Van Laere SJ, Luider TM, Martens JW, Foekens JA, Umar A.

J Natl Cancer Inst. 2014 Feb;106(2):djt376. doi: 10.1093/jnci/djt376. Epub 2014 Jan 7.

14.

Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes.

Peeters DJ, van Dam PJ, Van den Eynden GG, Rutten A, Wuyts H, Pouillon L, Peeters M, Pauwels P, Van Laere SJ, van Dam PA, Vermeulen PB, Dirix LY.

Br J Cancer. 2014 Jan 21;110(2):375-83. doi: 10.1038/bjc.2013.743. Epub 2013 Dec 24.

15.

Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival.

Bertucci F, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, Marsan M, Iwamoto T, Krishnamurthy S, Masuda H, Van Dam P, Woodward WA, Cristofanilli M, Reuben JM, Dirix L, Viens P, Symmans WF, Birnbaum D, Van Laere SJ.

Ann Oncol. 2014 Feb;25(2):358-65. doi: 10.1093/annonc/mdt496. Epub 2013 Dec 2.

16.

Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers.

Masuda H, Baggerly KA, Wang Y, Iwamoto T, Brewer T, Pusztai L, Kai K, Kogawa T, Finetti P, Birnbaum D, Dirix L, Woodward WA, Reuben JM, Krishnamurthy S, Symmans W, Van Laere SJ, Bertucci F, Hortobagyi GN, Ueno NT.

Breast Cancer Res. 2013 Nov 25;15(6):R112. doi: 10.1186/bcr3579.

17.

Presence of anaplastic lymphoma kinase in inflammatory breast cancer.

Robertson FM, Petricoin Iii EF, Van Laere SJ, Bertucci F, Chu K, Fernandez SV, Mu Z, Alpaugh K, Pei J, Circo R, Wulfkuhle J, Ye Z, Boley KM, Liu H, Moraes R, Zhang X, Demaria R, Barsky SH, Sun G, Cristofanilli M.

Springerplus. 2013 Oct 1;2:497. doi: 10.1186/2193-1801-2-497. eCollection 2013.

18.

Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting.

Peeters DJ, De Laere B, Van den Eynden GG, Van Laere SJ, Rothé F, Ignatiadis M, Sieuwerts AM, Lambrechts D, Rutten A, van Dam PA, Pauwels P, Peeters M, Vermeulen PB, Dirix LY.

Br J Cancer. 2013 Apr 2;108(6):1358-67. doi: 10.1038/bjc.2013.92. Epub 2013 Mar 7.

19.

Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets.

Van Laere SJ, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, Marsan M, Iwamoto T, Krishnamurthy S, Masuda H, van Dam P, Woodward WA, Viens P, Cristofanilli M, Birnbaum D, Dirix L, Reuben JM, Bertucci F.

Clin Cancer Res. 2013 Sep 1;19(17):4685-96. doi: 10.1158/1078-0432.CCR-12-2549. Epub 2013 Feb 8.

20.

The interaction between ER and NFκB in resistance to endocrine therapy.

Sas L, Lardon F, Vermeulen PB, Hauspy J, Van Dam P, Pauwels P, Dirix LY, Van Laere SJ.

Breast Cancer Res. 2012 Aug 31;14(4):212. doi: 10.1186/bcr3196. Review.

21.

Regulation of inflammatory breast cancer cell invasion through Akt1/PKBα phosphorylation of RhoC GTPase.

Lehman HL, Van Laere SJ, van Golen CM, Vermeulen PB, Dirix LY, van Golen KL.

Mol Cancer Res. 2012 Oct;10(10):1306-18. doi: 10.1158/1541-7786.MCR-12-0173. Epub 2012 Aug 15.

22.

Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers.

van Schooneveld E, Wouters MC, Van der Auwera I, Peeters DJ, Wildiers H, Van Dam PA, Vergote I, Vermeulen PB, Dirix LY, Van Laere SJ.

Breast Cancer Res. 2012 Feb 21;14(1):R34.

23.

A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer.

Trinh XB, Sas L, Van Laere SJ, Prové A, Deleu I, Rasschaert M, Van de Velde H, Vinken P, Vermeulen PB, Van Dam PA, Wojtasik A, De Mesmaeker P, Tjalma WA, Dirix LY.

Oncol Rep. 2012 Mar;27(3):657-63. doi: 10.3892/or.2011.1562. Epub 2011 Nov 24.

PMID:
22134540
24.

VEGF-A-independent and angiogenesis-dependent tumour growth in patients with metastatic breast cancer.

Trinh XB, van Dam PA, Vermeulen PB, Van Laere SJ, Van den Eynden GG, Tjalma WA, Dirix LY.

Clin Transl Oncol. 2011 Nov;13(11):805-8. doi: 10.1007/s12094-011-0737-3.

PMID:
22082645
25.

Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma.

Trinh XB, Tjalma WA, Dirix LY, Vermeulen PB, Peeters DJ, Bachvarov D, Plante M, Berns EM, Helleman J, Van Laere SJ, van Dam PA.

PLoS One. 2011;6(7):e22469. doi: 10.1371/journal.pone.0022469. Epub 2011 Jul 25.

26.

Circulating tumour cells in the central and the peripheral venous compartment in patients with metastatic breast cancer.

Peeters DJ, Van den Eynden GG, van Dam PJ, Prové A, Benoy IH, van Dam PA, Vermeulen PB, Pauwels P, Peeters M, Van Laere SJ, Dirix LY.

Br J Cancer. 2011 Apr 26;104(9):1472-7. doi: 10.1038/bjc.2011.122. Epub 2011 Apr 5.

27.

Array-based DNA methylation profiling for breast cancer subtype discrimination.

Van der Auwera I, Yu W, Suo L, Van Neste L, van Dam P, Van Marck EA, Pauwels P, Vermeulen PB, Dirix LY, Van Laere SJ.

PLoS One. 2010 Sep 7;5(9):e12616. doi: 10.1371/journal.pone.0012616.

28.

Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype.

Van der Auwera I, Limame R, van Dam P, Vermeulen PB, Dirix LY, Van Laere SJ.

Br J Cancer. 2010 Aug 10;103(4):532-41. doi: 10.1038/sj.bjc.6605787. Epub 2010 Jul 27.

29.

Quantitative methylation profiling in tumor and matched morphologically normal tissues from breast cancer patients.

Van der Auwera I, Bovie C, Svensson C, Trinh XB, Limame R, van Dam P, van Laere SJ, van Marck EA, Dirix LY, Vermeulen PB.

BMC Cancer. 2010 Mar 12;10:97. doi: 10.1186/1471-2407-10-97.

30.

Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer.

Van der Auwera I, Peeters D, Benoy IH, Elst HJ, Van Laere SJ, Prové A, Maes H, Huget P, van Dam P, Vermeulen PB, Dirix LY.

Br J Cancer. 2010 Jan 19;102(2):276-84. doi: 10.1038/sj.bjc.6605472. Epub 2009 Dec 1.

31.

Quantitative assessment of DNA hypermethylation in the inflammatory and non-inflammatory breast cancer phenotypes.

Van der Auwera I, Bovie C, Svensson C, Limame R, Trinh XB, van Dam P, Van Laere SJ, Van Marck E, Vermeulen PB, Dirix LY.

Cancer Biol Ther. 2009 Dec;8(23):2252-9. Epub 2009 Dec 19.

PMID:
19829046
32.

Inflammatory breast carcinoma as a model of accelerated self-metastatic expansion by intravascular growth.

Vermeulen PB, Van Laere SJ, Dirix LY.

Br J Cancer. 2009 Sep 15;101(6):1028-9; author reply 1030. doi: 10.1038/sj.bjc.6605251. Epub 2009 Aug 25. No abstract available.

33.

Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases.

Van den Eynden GG, Van Laere SJ, Van der Auwera I, Trinh XB, Van Marck EA, Dirix LY, Vermeulen PB.

Int J Cancer. 2009 Sep 15;125(6):1494-6. doi: 10.1002/ijc.24524. No abstract available.

34.

Re: Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells.

Van Laere SJ, Elst H, Peeters D, Benoy I, Vermeulen PB, Dirix LY.

J Natl Cancer Inst. 2009 Jun 16;101(12):895-6; author reply 896-7. doi: 10.1093/jnci/djp116. Epub 2009 Jun 9. No abstract available.

PMID:
19509352
35.

The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients.

Van der Auwera I, Elst HJ, Van Laere SJ, Maes H, Huget P, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY.

Br J Cancer. 2009 Apr 21;100(8):1277-86. doi: 10.1038/sj.bjc.6605013.

36.

The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer.

Trinh XB, Tjalma WA, Vermeulen PB, Van den Eynden G, Van der Auwera I, Van Laere SJ, Helleman J, Berns EM, Dirix LY, van Dam PA.

Br J Cancer. 2009 Mar 24;100(6):971-8. doi: 10.1038/sj.bjc.6604921. Epub 2009 Feb 24.

37.

A low frequency of lymph node metastasis in clear-cell renal cell carcinoma is related to low lymphangiogenic activity.

Baldewijns MM, Roskams T, Ballet V, Van den Eynden GG, Van Laere SJ, Van der Auwera I, Lerut E, De Bruïne AP, Thijssen VL, Vermeulen PB, van Poppel H.

BJU Int. 2009 Jun;103(12):1626-31. doi: 10.1111/j.1464-410X.2008.08272.x. Epub 2009 Jan 12.

38.

Aberrant methylation of the Adenomatous Polyposis Coli (APC) gene promoter is associated with the inflammatory breast cancer phenotype.

Van der Auwera I, Van Laere SJ, Van den Bosch SM, Van den Eynden GG, Trinh BX, van Dam PA, Colpaert CG, van Engeland M, Van Marck EA, Vermeulen PB, Dirix LY.

Br J Cancer. 2008 Nov 18;99(10):1735-42. doi: 10.1038/sj.bjc.6604705. Epub 2008 Oct 7.

39.

Gene expression profiles associated with the presence of a fibrotic focus and the growth pattern in lymph node-negative breast cancer.

Van den Eynden GG, Smid M, Van Laere SJ, Colpaert CG, Van der Auwera I, Bich TX, van Dam P, den Bakker MA, Dirix LY, Van Marck EA, Vermeulen PB, Foekens JA.

Clin Cancer Res. 2008 May 15;14(10):2944-52. doi: 10.1158/1078-0432.CCR-07-4397.

40.

NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation.

Van Laere SJ, Van der Auwera I, Van den Eynden GG, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY.

Br J Cancer. 2007 Sep 3;97(5):659-69. Epub 2007 Aug 14.

41.

Comparison of molecular determinants of angiogenesis and lymphangiogenesis in lymph node metastases and in primary tumours of patients with breast cancer.

Van den Eynden GG, Van der Auwera I, Van Laere SJ, Trinh XB, Colpaert CG, van Dam P, Dirix LY, Vermeulen PB, Van Marck EA.

J Pathol. 2007 Sep;213(1):56-64.

PMID:
17674348
42.

High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile.

Baldewijns MM, Thijssen VL, Van den Eynden GG, Van Laere SJ, Bluekens AM, Roskams T, van Poppel H, De Bruïne AP, Griffioen AW, Vermeulen PB.

Br J Cancer. 2007 Jun 18;96(12):1888-95. Epub 2007 May 15.

43.

Differential expression of hypoxia and (lymph)angiogenesis-related genes at different metastatic sites in breast cancer.

Van den Eynden GG, Van Laere SJ, Van der Auwera I, Gilles L, Burn JL, Colpaert C, van Dam P, Van Marck EA, Dirix LY, Vermeulen PB.

Clin Exp Metastasis. 2007;24(1):13-23. Epub 2007 Feb 13.

PMID:
17295094
44.

Induction of lymphangiogenesis in and around axillary lymph node metastases of patients with breast cancer.

Van den Eynden GG, Van der Auwera I, Van Laere SJ, Huygelen V, Colpaert CG, van Dam P, Dirix LY, Vermeulen PB, Van Marck EA.

Br J Cancer. 2006 Nov 20;95(10):1362-6. Epub 2006 Oct 31.

45.

Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding.

Van Laere SJ, Van der Auwera I, Van den Eynden GG, Elst HJ, Weyler J, Harris AL, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3249-56.

46.

Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunohistochemical study.

Van den Eynden GG, Van der Auwera I, Van Laere SJ, Colpaert CG, van Dam P, Dirix LY, Vermeulen PB, Van Marck EA.

Br J Cancer. 2006 Jun 5;94(11):1643-9.

47.

Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study.

Van der Auwera I, Van den Eynden GG, Colpaert CG, Van Laere SJ, van Dam P, Van Marck EA, Dirix LY, Vermeulen PB.

Clin Cancer Res. 2005 Nov 1;11(21):7637-42.

48.

Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling.

Van Laere SJ, Van den Eynden GG, Van der Auwera I, Vandenberghe M, van Dam P, Van Marck EA, van Golen KL, Vermeulen PB, Dirix LY.

Breast Cancer Res Treat. 2006 Feb;95(3):243-55. Epub 2005 Oct 27.

49.

Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer.

Van den Eynden GG, Van der Auwera I, Van Laere SJ, Colpaert CG, Turley H, Harris AL, van Dam P, Dirix LY, Vermeulen PB, Van Marck EA.

Br J Cancer. 2005 Nov 14;93(10):1128-36.

50.

Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer.

Van den Eynden GG, Van Laere SJ, Van der Auwera I, Merajver SD, Van Marck EA, van Dam P, Vermeulen PB, Dirix LY, van Golen KL.

Breast Cancer Res Treat. 2006 Feb;95(3):219-28. Epub 2005 Oct 22.

Supplemental Content

Loading ...
Support Center